Welcome to our dedicated page for Mitesco SEC filings (Ticker: MITI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mitesco, Inc. (MITI) files a range of SEC documents that provide detailed insight into its business evolution, capital structure and technology-focused strategy. Its registration statements on Form S‑1 and S‑1/A describe Mitesco as a smaller reporting company incorporated in Nevada, outline its history from earlier business lines through the closure of The Good Clinic operations, and explain its current emphasis on data center and cloud computing activities through its Centcore unit, along with venture and software initiatives under Vero Technology Ventures.
These S‑1 filings also register shares of common stock for resale by selling stockholders, including shares issued in connection with the restructuring of promissory notes, accounts payable and preferred stock, as well as shares issuable upon redemption or conversion of Series A Amortizing Convertible Preferred Stock and bridge notes. The prospectus sections discuss risk factors, use of proceeds for selling stockholders, and the company’s status as a smaller reporting company whose common stock trades on the OTC‑QB Venture Market under the symbol MITI.
Mitesco’s current reports on Form 8‑K and 8‑K/A add further detail on material events and securities issuances. These filings describe the creation and terms of the Series A Amortizing Convertible Preferred Stock, dividend payments on Series X Preferred Stock in restricted common shares, redemptions and conversions of preferred stock, and the issuance of common shares to consultants involved in developing the company’s Robo Agent software application. Other 8‑K filings disclose senior secured convertible bridge notes, advisory agreements related to potential uplisting of the company’s securities, and press releases about expansion plans and data center initiatives.
Through Stock Titan’s SEC filings page, users can access these documents as they are made available on EDGAR and review them alongside AI-powered summaries that highlight key terms, structural changes and business descriptions. Investors can quickly locate Mitesco’s annual and quarterly reports, registration statements, and current reports, as well as disclosures about preferred stock structures, insider-related equity issuances and financing arrangements. This consolidated view helps readers understand how Mitesco’s regulatory filings reflect its shift toward data center services, cloud computing ventures and A.I.-enabled software, while also tracking the company’s ongoing restructuring of legacy obligations.
Mitesco, Inc. has registered up to 106,836,091 shares of common stock for resale by existing stockholders. These shares include stock issued and issuable from a large debt restructuring, redemptions of Series A Amortizing Convertible Preferred Stock, prior unregistered issuances, and potential conversion of 2025 Bridge Notes. Mitesco will not receive any proceeds from these sales; all cash goes to selling stockholders.
The company is shifting from a shuttered clinic business to new data center and cloud ventures through its Centcore and Vero Technology Ventures units. As of December 29, 2025, it had 15,093,055 common shares outstanding, and full redemption of Series A Preferred could add about 97.8 million shares, creating very significant dilution. The company reports current liabilities of about $17.6 million, minimal cash, a history of losses, and its auditors and management note substantial doubt about its ability to continue as a going concern.
Mitesco, Inc. has filed a resale prospectus covering up to 106,836,091 shares of common stock, all to be sold from time to time by existing stockholders. The shares include 2,628,179 shares issued to cancel approximately $12.4 million of obligations, up to 97,779,013 shares tied to the redemption of Series A Preferred Stock, 2,762,233 previously issued shares, and up to 3,666,666 shares from potential conversion of 2025 Bridge Notes.
The company is not selling securities itself in this offering and will receive no proceeds from these resales. Shares outstanding were 15,093,055 as of December 29, 2025, and could rise to 115,524,531 if all Series A redemption and Bridge Note conversion shares are issued. The filing follows a large debt restructuring that converted about $24 million of obligations into equity and preferred stock.
Mitesco has exited its former clinic business and now operates as a holding company focused on data center services and AI-based software through its Centcore and Vero Technology Ventures units. As of September 30, 2025, it held approximately $300 in cash against about $17.6 million in current liabilities and discloses substantial doubt about its ability to continue as a going concern. The company also warns that redemption of Series A Preferred Stock could cause over 90% dilution to existing common shareholders.
Mitesco, Inc. has filed a Form S-1 registering up to 106,836,091 shares of common stock for resale by existing investors, with the company itself not selling any securities and receiving no proceeds from these sales.
The shares include stock issued or issuable from a large debt restructuring, notably up to 97,779,013 shares tied to the redemption of Series A Preferred Stock and 3,666,666 shares from potential conversion of 2025 bridge notes. Mitesco had 15,093,055 shares outstanding as of December 29, 2025, and projects up to 115,524,531 shares outstanding if all Series A redemptions and bridge note conversions occur, implying substantial potential dilution. The filing also discloses a history of losses, heavy legacy obligations, and an auditor-raised substantial doubt about its ability to continue as a going concern absent new capital and meaningful revenue growth.
Mitesco, Inc. entered into two Senior Secured 10% Original Issue Discount Convertible Promissory Notes with C/M Capital Master Fund, L.P. and WVP Emerging Manager Onshore Fund, LLC. The notes provide initial funding of $150,000 and $100,000, for a total of $250,000, and each investor may later fund up to $1,000,000 in total.
The 18‑month notes require repayment of $275,000 in aggregate, reflecting the 10% original issue discount, and bear no interest unless in default. They are convertible into Mitesco common stock at $0.15 per share, subject to adjustments, and are guaranteed by the company’s subsidiaries with a first priority senior security interest in all company assets. The securities were sold as unregistered offerings under Section 4(a)(2) and Regulation D.
Mitesco, Inc. reported that it issued a press release on December 9, 2025 to update shareholders on its business development plans. The company stated it intends to explore expanding its data center operations in Tennessee, highlighting the state’s relatively low power costs as a key factor. It also discussed the possibility of pursuing a merger or acquisition to accelerate growth compared with relying solely on organic expansion. The press release is attached to the report as an exhibit.
Mitesco, Inc. is registering up to 105,002,758 shares of common stock for resale by existing stockholders. The company itself is not selling securities and will receive no proceeds from these sales. The registered shares include stock issued and issuable in a large debt restructuring, shares underlying Series A Amortizing Convertible Preferred Stock, previously issued common shares, and shares related to a 2025 convertible bridge note.
Mitesco has shifted from a discontinued clinic business to a holding-company model focused on data center services through Centcore and cloud and AI software ventures through Vero Technology Ventures. As of December 4, 2025, 15,093,055 common shares were outstanding, with total shares potentially reaching 113,691,198 if Series A Preferred redemptions and the bridge note conversion occur. The company reports substantial doubt about its ability to continue as a going concern, with minimal cash, significant liabilities, and a need for additional capital.
The filing highlights extensive risks, including severe potential dilution from Series A Preferred redemptions, settlement obligations from prior clinic leases and vendors, thin and volatile trading in its stock, cybersecurity threats, intense competition in data services, evolving regulatory requirements, and execution risk around its acquisition and growth strategy.
Mitesco, Inc. entered into a six‑month Advisory Agreement with JRB Consulting, Inc. to support acquisitions, financing efforts, and an uplisting of its securities to a senior exchange such as NASDAQ or the NYSE. As compensation, Mitesco will pay JRB a cash fee of $200,000 upon completion of an approved uplisting and has immediately issued 250,000 shares of restricted common stock, which will be included on a piggyback basis in a future registration statement.
The company states that the shares were issued to accredited institutional investors in a private transaction under Section 4(a)(2) of the Securities Act. Mitesco also released a press update describing its enterprise AI sales‑force automation application called “Robo Agent”, its goal of moving to a senior trading exchange, and the possibility of pursuing a merger or acquisition to accelerate growth beyond organic expansion.
Mitesco, Inc. filed its Q3 2025 report, showing severe liquidity and ongoing restructuring. The company ended the quarter with cash and cash equivalents of $321 and a stockholders’ equity deficit of $(23,785,020). Management disclosed “substantial doubt” about its ability to continue as a going concern.
Q3 revenue was $3,000 (down from $23,500 a year ago) as resources shifted to software projects. Operating expenses were $1,014,422, and the company reported a Q3 net loss of $(3,202,971), driven by accretion and revaluations tied to its Series A preferred and a $(500,000) legal settlement loss. For the nine months, revenue was $38,700 and net income was $159,981, aided by a $3,513,655 gain on derivative revaluation.
Current liabilities totaled $17,583,270, including legal settlements of $3,322,834 and Series A preferred liabilities presented at a $13,397,721 present value. The company issued common shares for redemptions and services and recorded stock-based compensation of $824,649 year-to-date. As of November 13, 2025, common shares outstanding were 15,093,055.
Mitesco, Inc. (MITI) entered a secured financing and unregistered equity securities transaction. The company issued a Senior Secured 10% Original Issue Discount Convertible Promissory Note with potential total funding of $1,000,000, beginning with $250,000 funded on October 31, 2025. The 18‑month note requires repayment of $275,000 reflecting the 10% OID, bears no interest unless in default, and is convertible into common stock at $0.15 per share, subject to adjustments.
The note may be prepaid at 110% of the outstanding principal. Obligations are guaranteed by subsidiaries, secured by a pledge of subsidiary securities, and carry a first‑priority senior security interest in all company assets. The securities were sold pursuant to Section 4(a)(2) and Regulation D and are not registered under the Securities Act.
Mitesco, Inc. (MITI) reported an insider transaction by CEO and director Mack R. Leath. On 09/22/2025, Leath acquired 8,787 shares of common stock at $0.18 per share. Following this trade, he beneficially owned 394,327 shares, held directly. A footnote states this total includes 100,000 shares held by a family member.